...
首页> 外文期刊>Medical science monitor : >Blood serum levels of soluble forms of adhesion molecules ICAM-1 (sICAM-1)and selectin E (s-selectin E) in patients with various phases of non-Hodgkin's lymphomas.
【24h】

Blood serum levels of soluble forms of adhesion molecules ICAM-1 (sICAM-1)and selectin E (s-selectin E) in patients with various phases of non-Hodgkin's lymphomas.

机译:非霍奇金淋巴瘤各期患者的可溶性形式粘附分子ICAM-1(sICAM-1)和选择素E(s-selectin E)的血清水平。

获取原文

摘要

BACKGROUND: Monitoring of disease activity and effectiveness of treatmentplays an important role in curative management of patients with non-Hodgkin's lymphomas (n-HL). In thesearch for markers useful for biochemical monitoring of n-HL patients, a group of proteins called adhesionmolecules attracted attention. Particular attention has been devoted to sICAM-1 (intercellular adhesionmolecule-1). A correlation between sICAM-1 levels and histological malignancy grades and clinical stagingof n-HL, activity of the disease and tumor mass has been observed. The aim of the study was to assessthe utility of determining serum levels of selected adhesion molecules in n-HL monitoring. The studywas carried out in 60 patients with intermediate and high malignancy grade n-HL according to WorkingFormulation (anaplastic, lymphoblastic, immunoblastic, centroblastic and centroblastic-centrocytic).MATERIAL/METHODS: Soluble ICAM-1 adhesion molecule (sICAM-1) and selectin E levels were determined inthe sera of 31 newly diagnosed patients, 18 with complete remission, and 11 with relapse of the disease.The control group consisted of 15 healthy subjects. The results were expressed in ng/ml. RESULTS: sICAM1levels were similar in healthy controls and patients in the remission phase and significantly lower inpatients with diagnosed active disease and relapses. Relapses were associated with slightly lower levels(on borderline of statistical significance) than of diagnosis Serum selectin E levels, however, demonstratedno differences among patient groups or as compared with controls. CONCLUSIONS: The presented resultsindicate the utility of serum sICAM-1 level determination in assessment of activity of intermediate andhigh malignancy grade non-Hodgkin's lymphomas.
机译:背景:疾病活动性和治疗效果的监测在非霍奇金淋巴瘤(n-HL)患者的治愈管理中起着重要作用。在寻找可用于n-HL患者生化监测的标记物时,一组称为粘附分子的蛋白质引起了人们的关注。 sICAM-1(细胞间粘附分子-1)已引起特别关注。已经观察到sICAM-1水平与组织恶性程度和n-HL的临床分期,疾病活性和肿瘤块之间的相关性。该研究的目的是评估在n-HL监测中确定所选粘附分子血清水平的实用性。根据WorkingFormulation(间变性,淋巴母细胞,免疫母细胞,中心母细胞和中心母细胞-中心细胞)对60例中度和高度恶性级别n-HL患者进行了研究。材料/方法:可溶性ICAM-1粘附分子(sICAM-1)和选择素测定31例新诊断患者的血清E水平,18例完全缓解,11例疾病复发。对照组由15名健康受试者组成。结果以ng / ml表示。结果:健康对照和缓解期患者的sICAM1水平相似,确诊为活动性疾病和复发的住院患者明显降低。复发所致的水平略低于诊断水平(在统计学上有统计学意义),但血清选择素E水平却与对照组相比无差异。结论:本研究结果表明血清sICAM-1水平测定可用于评估中,高恶性级非霍奇金淋巴瘤的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号